rsRolesWithAccess DOES NOT exist
InDevEnvironment=false
rsRolesWithAccess numRows = [0]
IsInternalUser=[false]
InDevEnvironment=[false]
IsSectionSecure=[false]
Authorized=[false]
LMSAccess=[false]
HasNeuroHCP=[false]
UserLoggedIn=[false]
Is NOT logged in - In Dev environment:false

Diagnosis and Treatment

AUA/SUFU guidelines

The American Urological Association and Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction Guideline for the diagnosis and treatment of overactive bladder in adults is to provide a clinical framework for the diagnosis and treatment of non-neurogenic overactive bladder. The guidance lists Percutaneous Tibial Nerve Stimulation (PTNS), otherwise known as PTNM, as an acceptable treatment in a carefully selected patient population.

The most common protocol was the application of 30 min of stimulation once a week for 12 weeks. The Panel interpreted these data to indicate that PTNM can benefit a carefully selected group of patients characterized by moderately severe baseline incontinence and frequency and willingness to comply with the PTNM protocol.1

Prevalence of overactive bladder

Prevalence of OAB and FI vs. Other Health Conditions in the United States

The number of overactive bladder (OAB) patients is staggering. OAB is more common than diabetes and the incidence increases every year as the baby boomer population ages.4,9

  • More than 37 million people in the United States – 1 in 6 adults – suffer from OAB2,3
  • Both men and women
  • All ages

Reticence in seeking help

In spite of this high prevalence, the number of patients presenting OAB symptoms to their clinician is much lower. Many symptomatic patients will not present to their provider for treatment10-12 because they see symptoms as a nuisance or as an embarrassment.13-15

Millions of OAB patients are looking for a treatment option that can restore* bladder function and help them improve their quality of life.

Unmet needs

Patient compliance with medications, such as anticholinerginics (ACs), is low due to variable efficacy and side effects, such as dry mouth and constipation.1 As many as 7 in 10 patients give up taking medication within 6 months.16,17

*With PTNM, restored bladder function is defined as a measurable reduction in urinary frequency and/or urinary incontinence episodes following treatment.


References

  1. Gormley, A.E., Lightner, D.J., Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline Amendment.J Urol. 2015 193(5) 1572-1580
  2. Stewart WF, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003:327-336.
  3. United Nations, Department of Economic and Social Affairs, Population Division (2011). World Population Prospects: The 2010 Revision, CD-ROM Edition.
  4. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics Report, 2014. http://www.cdc.gov/diabetes/pubs/ statsreport14/national-diabetes-report-web.pdf. Accessed December 20, 2016
  5. United States Quick Facts. United States Census Bureau Web site. Available at: https://www.census.gov/quickfacts/table/PST045215/00. Accessed December 20, 2016.
  6. Whitehead WE, Borrud L, Goode PS, et al. Fecal incontinence in US adults: epidemiology and risk factors. Gastroenterology. 2009;137:512-517.
  7. Centers for Disease Control and Prevention. 2014 NHIS Data. http://www.cdc.gov/ asthma/nhis/2014/table3-1.htm. Accessed December 20, 2016.
  8. Alzheimer's Association. Alzheimer's facts and figures. www.alz.org/alzheimers_disease_facts_and_figures.asp. Accessed February 8, 2016.
  9. Coyne, K. S., C. C. Sexton, et al. (2011). National community prevalence of overactive bladder in the United States stratified by sex and age. Urology 77(5): 1081-1087.
  10. Hashim H, Abrams P. Overactive bladder: an update. Curr Opin Urol. 2007;17(4):231-236.
  11. Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology. 2004;63(3):461-465.
  12. Ricci JA, Baggish JS, Hunt TL, et al. Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin Ther. 2001;23(8):1245-1259.
  13. Erdem N, Chu FM. Management of overactive bladder and urge urinary incontinence in the elderly patient. Am J Med. 2006;119(3 suppl 1):29-36.
  14. Hu TW, Wagner TG. Economic considerations in overactive bladder. Am J Manag Care. 2000;6(11 suppl):S591-S598.
  15. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760-766.
  16. Haab, F. and D. Castro-Diaz (2005). "Persistence with antimuscarinic therapy in patients with overactive bladder." Int J Clin Pract 59(8): 931-937.
  17. Yeaw, J., J. S. Benner, et al. (2009). "Comparing adherence and persistence across 6 chronic medication classes." J Manag Care Pharm 15(9): 728-740.

SHOW PATIENTS THEIR OPTIONS

View OAB care pathway >

SHOW PATIENTS THEIR OPTIONS

View OAB care pathway >